Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

被引:1076
|
作者
Brugarolas, J
Lei, K
Hurley, RL
Manning, BD
Reiling, JH
Hafen, E
Witter, LA
Ellisen, LW
Kaelin, WG [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02116 USA
[4] Dartmouth Coll, Dept Med & Biochem, Dartmouth Med Sch, Hanover, NH 03755 USA
[5] Dartmouth Coll, Dept Sci Biol, Hanover, NH 03755 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[7] Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland
[8] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
tuberous sclerosis complex; TSC1; TSC2; REDD1/RTP801; mTOR; hypoxia;
D O I
10.1101/gad.1256804
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.
引用
收藏
页码:2893 / 2904
页数:12
相关论文
共 50 条
  • [21] TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth
    Gao, XS
    Pan, DJ
    GENES & DEVELOPMENT, 2001, 15 (11) : 1383 - 1392
  • [22] Mutational analysis of TSC1 and TSC2 genes in gangliogliomas
    Becker, AJ
    Löbach, M
    Klein, H
    Normann, S
    Nöthen, MM
    von Deimling, A
    Mizuguchi, M
    Elger, CE
    Schramm, J
    Wiestler, OD
    Blümcke, I
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2001, 27 (02) : 105 - 114
  • [23] Molecular and Functional Assessment of TSC1 and TSC2 in Individuals with Tuberous Sclerosis Complex
    Dufner-Almeida, Luiz Gustavo
    Cardozo, Lais F. M.
    Schwind, Mariana R.
    Carvalho, Danielly
    Almeida, Juliana Paula G.
    Cappellano, Andrea Maria
    Alegria, Thiago G. P.
    Nanhoe, Santoesha
    Nellist, Mark
    Passos-Bueno, Maria Rita
    Chiavegatto, Silvana
    Silva, Nasjla S.
    Rosemberg, Sergio
    Pereira, Ana Paula A.
    Antoniuk, Sergio Antonio
    Haddad, Luciana A.
    GENES, 2024, 15 (11)
  • [24] Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
    Rosengren, Thomas
    Nanhoe, Santoesha
    Dufner de Almeida, Luis Gustavo
    Schonewolf-Greulich, Bitten
    Larsen, Lasse Jonsgaard
    Brunbjerg Hey, Caroline Amalie
    Duno, Morten
    Ek, Jakob
    Risom, Lotte
    Nellist, Mark
    Moller, Lisbeth Birk
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [25] Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations
    Rendtorff, ND
    Bjerregaard, B
    Frödin, M
    Kjaergaard, S
    Hove, H
    Skovby, F
    Brondum-Nielsen, K
    Schwartz, M
    HUMAN MUTATION, 2005, 26 (04) : 374 - 383
  • [26] The role of TSC1 and TSC2 proteins in neuronal axons
    Karalis, Vasiliki
    Wood, Delaney
    Teaney, Nicole A.
    Sahin, Mustafa
    MOLECULAR PSYCHIATRY, 2024, 29 (04) : 1165 - 1178
  • [27] Identification of TSC1 and TSC2 Mutations in Korean Patients With Tuberous Sclerosis Complex
    Jang, Mi-Ae
    Hong, Seung Bong
    Lee, Jee Hun
    Lee, Mun Hyang
    Chung, Man Pyo
    Shin, Hyung-Jin
    Kim, Jong-Won
    Ki, Chang-Seok
    PEDIATRIC NEUROLOGY, 2012, 46 (04) : 222 - 224
  • [28] Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex
    Yamamoto, T
    Pipo, JR
    Feng, JH
    Takeda, H
    Nanba, E
    Ninomiya, H
    Ohno, K
    BRAIN & DEVELOPMENT, 2002, 24 (04): : 227 - 230
  • [29] Mutational analysis of TSC1 and TSC2 in Danish patients with tuberous sclerosis complex
    Thomas Rosengren
    Santoesha Nanhoe
    Luis Gustavo Dufner de Almeida
    Bitten Schönewolf-Greulich
    Lasse Jonsgaard Larsen
    Caroline Amalie Brunbjerg Hey
    Morten Dunø
    Jakob Ek
    Lotte Risom
    Mark Nellist
    Lisbeth Birk Møller
    Scientific Reports, 10
  • [30] Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex
    Li, Yi
    Barkovich, Matthew J.
    Karch, Celeste M.
    Nillo, Ryan M.
    Fan, Chun-Chieh
    Broce, Iris J.
    Tan, Chin Hong
    Cuneo, Daniel
    Hess, Christopher P.
    Dillon, William P.
    Glenn, Orit A.
    Glastonbury, Christine M.
    Olney, Nicholas
    Yokoyama, Jennifer S.
    Bonham, Luke W.
    Miller, Bruce
    Kao, Aimee
    Schmansky, Nicholas
    Fischl, Bruce
    Andreassen, Ole A.
    Jernigan, Terry
    Dale, Anders
    Barkovich, A. James
    Desikan, Rahul S.
    Sugrue, Leo P.
    SCIENTIFIC REPORTS, 2018, 8